Upload
john-redaelli
View
133
Download
1
Tags:
Embed Size (px)
Citation preview
Hyung Min Chung
Konkuk University, College of Medicine,Seoul, Korea
2014 MFDS Meeting2014. 7. 9~10.
2014 MFDS Global Biopharmaceutical Forum
Ideal Cell Sources for Stem Cell Therapy???
Ideal Cells for Application
Embryonic Stem CellsSCNT-derived ESCsParthenogenic embryo-derived ESCsSingle blastomere-derived ESCs
Induced Pluripotent Stem CellsDirect Conversion
Mid brain tissue from aborted fetus
Autologous Adult Stem CellsAdipose-derivedPeripheral blood-derivedBone marrow-derivedTesticular stem cells (HTSC)
Allogeneic Adult Stem CellsCord blood-derivedPlacenta-derivedWharton’s jelly
HLA typing of 38 CHA-hESC lines vs 6740 donated cord bloodsfor simulation of stem cell transplantation
050
100150200250300350
A, B antigen and DRB1
allele level (2 mismatch)
A, B and DRB1 allele level
(2 mismatch)
Full match 1 mismatch 2 mismatch
A, B antigen and DRB1 allele level 0.3% 2.43% 22.4%
A, B and DRB1 allele level 0.21% 1.74% 14.21%
Cell Transplantation, 2010
56 hESCs established Successful derivate SCNT-hESC linesProduction of Single Blastomere derived hESCDevelopment of 100 clinical grade hESCs establishment
Human ES Cell Bank : overcome histocompatability
It was estimated that our 38 CHA-hESC lines can provide a coverage for 27% and 45% of the Korean population with A, B, DR allele level and A, B antigen/DR allele level matches, respectively.
National Stem Cell Bank
Human ES Cell Product – RPE Program for Blindness
2009 2010, 2011, 2012
Products Company Tg Diseases Status
OPC(Oligodendrocytesprogenitor cells)
Geron Spinal Cord Injury
Phase I (2009.01)
Discontinued(November, 2011.11)
hES-RPEAdvanced Cell
Technology, Inc.SMD
Dry-AMDPhase I/IIa (2010.11)Phase I/IIa (2011.01)
hES-RPE CHABIO&DIOSTECH, Inc.
SMDDry-AMD
MMD
Phase I (2011.05)Phase I/IIa (2012.05)Phase I/IIa (2013.11)
hES-RPE Pfizer AMD Expected in Europe
hES-RPE Cell cure Neuroscience AMD Expected in Europe
iPS-RPE RIKEN AMD Approval of IND (2014)
Blindness
Accumulation of Drugen Cause by death of perivascular mural cell
RPE Therapy PVPC Therapy
Stargardt Macular DystrophyAge related Macular Degeneration Diabetic/Ischemic Retinopathy
Human ES Cell Therapy : Blindness
Dry AMD(90%) Wet AMD(10%)
PROVIDE nutrients and growth factors- photoreceptors see no blood
RECYCLES vitamin A - maintains photoreceptor layer
DETOXIFIES photoreceptor layer MAINTAINS Bruch’s membrane
- natural antiangiogenic barrier - immune privilege of retina
ABSORBS stray light/protects from UV
Retinal Pigment Epithelium
1. Target Disease : Blindness (Age related Macular Degeneration, Retinitis Pigmentosa, Stardgart’s disease
2. Clinical study process is ongoing
- November 19, 2009 : pre-clinical activities in preparation of the first IND filing with the FDA (USA)
- March 2010: Granted Orphan Drug Status from US FDA for Treatment of Stargardt’s Macular Dystrophy
- May 2011: Approval of clinical trial in KFDA for SMD (Phase I)
- May 2012 : Approval of clinical trial in kFDA for Dry-AMD (Phase I/IIa)
- Nov 2013: Approval of clinical trial in kFDA for MMD (Phase I/IIa)
Blindness (Stargardt’s Disease, Age-Related Macular Degeneration)
Dry AMD(90%) Wet AMD(10%)
EB-DM (8주) RGM- RGMM (4주)MEF-GM & hES-GM (2주)
FM(유효기간 3개월) IP-Process (4시간 이내)
MEF 세포배양 &
hES 세포의 증식EB의 형성과성장 hRPE세포의 증식과 분화 hRPE세포의 증식과 분화
수집, 충전 동결보존 임상의약품 출하 임상시술
Operation
Generation of RPE from hESCs
CHA-RPE lot #-001 CHA-RPE lot #-002 CHA-RPE lot #-003
ZO-1 MITF BestrophinPax-6
Purity and Gene Expression
OCT4
Nanog DAPI
RPE
hES-
MA
09
Sir T
1D
API
MEF RPE
Removal of Stemness Cells & Mouse MEF cells
0.001
0.1
10
1000
Fold
(2^
-ddCT)
RPE Lot 2RPE Lot 1
Gene expression
Storage and COA제 품 개 요
임상시험용 401제 품 명: MA09-hRPE제품번호 :RPE-0006(CRP120921)용 량 : 2 x 106 Cells/mL유효 기간: 2013. 01. 23
○ 완제품 보관장소
완제품 보관실에 비치된 vapor type LN2 탱크(<-135℃ )
○ 제품성적서
ERG response at P60: Amplitude (uV)
α-wave (outer)
β-wave (inner)
β-cone wave
NegativeControl 5 38 28
Test Group 35 110 59
ERG(Electroretinogram)
Test Product
Cycles/degree
NegativeControl
untreated 0.21 ± 0.03
sham 0.29 ± 0.03
Test Group hES-RPE 0.42 ± 0.03
Positive Control
(Normal)untreated 0.6
Optomotor Test
TestProduct
2.7log Unit
NegativeControl
untreated 0 %
sham 18 %
Test Group hES-RPE 52 %
Luminance Threshold
Preclinical Outcomes (1)
Histology Analysis
Test Product ONL LyersPositive Control
(Normal rat)untreated 10-12 deep
Test Group hES-RPE 5-7 deep
Negative Control untreated Single deep
A. Test Group
B. Negative Control C. Test Group: human nuclear marker
1. Proof of Concept Study: RCS rat
Preclinical Test : RP, AMD model
RPE Engraftment – Mouse Model
Human hES-RPE cells engraft and align with mouse RPE cells in mouse eye
For each set: Panel (C) is a bright field image
and Panel (D) shows immunofluorescence
with anti-human bestrophin (green) and anti-
human mitochondria (red) merged and
overlayed on the bright field image.
Magnification 400x
Lancet, 2012
Optomotor Test Results
GroupUn-treated
sham 5K 20K 50K 75K 100K
Normalrat
Cycle/degree 0.16 0.18 0.24 0.28 0.44 0.41 0.43 0.6
Preclinical Test : Dose Finding Data
Luminance Threshold Test
DoseMedium
only 20K 50K 75K 100K
2.2log Unit 3% 28% 45% 40% 65% (Non
significant)
Blue Line: RPERed Line: sham
20K
100K75K
50K
GLP InstituteSinclair Research (non-GLP)Wuxuasse, MO, USA
Study Product hES-RPE, (100,000 cells)
Route for Injection Subretinal injection
Animal Model NIH-III nude mice
Duration of Study 6 months
Exp. Design
Test Results No observation of tumor (including teratoma) formation in hES-RPE injection group
Group Duration Test cells No. of mice
12 mo 99.99% hRPE cells/
0.01% hES
8
6 mo 8
22 mo 99.9% hRPE cells/
0.1% hES
8
6 mo 8
32 mo 99% hRPE cells/
1% hES
8
6 mo 8
42 mo
100 % hES8
6 mo 8
Preclinical Test : Tumorogenicity
WeeksTeratomaFormation hESC RPE
4 Malignant4/6
(66.67%)0/6(0%)
12 Malignant 5/7(71.43%)
0/7(0%)
40 Malignant8/9
(88.89%)0/11(0%)
Teratoma formation
P<0.0001
Biodistribution
3
4
2
1
▶ Pathologies not observedAll eye slides were reviewed by a board certified veterinary pathologists
Only typical retinal morphology
No ectopic tissue or abnormal pathology
Histological examination: the presence of human-specific nuclear marker
Negative staining for human-specificproliferating cell nuclear antigen (PCNA)
Preclinical Study - Safety
Phase I/IIa Clinical Trial Design : Dry-AMD
12 patients for each trial, ascending dosages of 50K, 100K, 150K and 200K cells. - For each cohort, 1st patient treatment followed by 6 weeks DMSB review
before remainder of cohort.
Patients will be monitored weekly – including high definition imaging of retina
High Definition Spectral Domain Optical Coherence Tomography (SD-OCT) Retinal AutofluorescenceAdaptive Optics Scanning Laser Ophthalmoscopy (AOSLO)
Permit comparison of RPE and photoreceptor activity before and after treatment
50K cells 100K cells 150K cells 200K cells
DSMB review
First Human Trials in AMD & SMD
21 SMD Patients Treated
12 patients (50K cell cohort) treated – US, UK & Korea Trials
8 patients (100K cells cohort) treated – US & UK Trials
1 patients (150K cells cohort) treated – US Trials15 Dry-AMD Patients Treated
8 patients (50K cell cohort) treated – US & Korea Trials
5 patients (100K cells cohort) treated – US Trials
2 patients (150K cells cohort) treated – US Trials
Designate the Orphan Drug at 2014 !
Jules Stein Eye InstituteSteven D. Schwartz, MD
BascomPalmer Eye Institute
Byron L. Lam, MD Wills Eye InstituteCarl D. Regillo, MD
Bascom Palmer Eye InstitutePhilip J. Rosenfeld, MD PhD
Massachusetts Eye and Ear Infirmary
Dean Eliott, MD
Edinburgh Royal InfirmaryBaljean Dhillon Bmed Sci, BM Bs, FRCS
Moorfields Eye Hospital James Bainbridge, MA MB Bcir PhD FRCOphth
London
Cha Hospital Won-kyung Song, MD PhD
Other Human ES Cell Products and Related Technologies
Stem Cell Differentiation into Perivascular Progenitor Cells (PVPCs)Cardiac Muscle Cells (CMs)
In vivo POC
Perivascular Progenitor Cell Program
Accumulation of Drugen Cause by death of perivascular mural cell
RPE Therapy PVPC Therapy
Stargardt Macular DystrophyAge related Macular Degeneration
Diabetic/Ischemic Retinopathy
Concept of PeriVascular Progenitor Cell
• Multipotent MSC-like cellmesodermal multipotent cell, perivascular cell, vascular MSC
PeriVascular Progenitor Cell
• PVPCs , principally pericytes, were identified in multiple human organs including sketal muscle, pancreas, adipose tissue and placenta.
• Pericyte density has been described for neural tissues, in particular the retina.
• PVPCs perform an important role in blood vessel homeostasis.
• PVPCs have no pan marker, but long term cultured PVPCs stably expressed NG2, CD146 and PDGFR.
• They express all makers of MSC such as CD44, CD73, CD90, CD105.
• In contrast, they do not express the markers of hematopoietic, endothelial and myogenic cell.
hESC-PVPC Derivation
Derivation of PVPC
• Non-sorted cell derivation – natural selection
• Matrix-dependant single cell attachment- induced CD44 expression, - natural selection of PDGFR-b- population
• CHA-3, CHA-5, CHA-9, CHA15, CHA11, H9 hESC-PVPC
• Up to 35th passage, stable, single layer
calcein dye transfer assay
Functional Gap Junction Formation between hESC-PVPCs and Other Vascular Cells
hESC-PVPC Recruitment during Vasculogenic Tube Assembly
In vitro 3D collagen matrix models of endothelial lumen formation during vasculogenesis
In vivo localization of hESC-PVPC in mouse STZ-diabetic retinopathy model
• Smooth Muscle like Cells
Differentiation Potentials
adipogenesis
osteogenesis
Oil-red staining
Von Kossa’s staining
• Adipose, Chondrocyte, Osteoblast cells
vSMC (vascular smooth muscle cell) Differentiation
Two different types of SMCcontraction
Derivation of SMPC in vivo vasclugenesis
0min 30min
Carbachol (10-5M)
hESC-BFC (brown fat cell) & Myocyte
BFC vs. WFC Myocyte
Cell sheet using Poly-NIPAAM coated plate
Cardiomyocyte sheetor cardiac patch
transplanted to ischemic hearts as cardiac patches
Osteocyte differentiated from hESC-PVPC
Myocyte differentiated from hESC-PVPC
Improvement of Blood Vessel Permeabilization
normal mouse retina STZ diabetic mouse retina(12week) hESC-PVPC injected-STZ diabetic mouse retina(12week)
Intravitreous injection of MSCs in STZ diabetic mice
BN-STZ 6wk
BN-CTL 6wk
BN-STZ 6wk (PVPC 5x104 T.P. 4wk)
Improvement of Blood Vessel Permeabilization
Dextran DiI
Transplanted hESC-PVPCs take on Characteristics of Retinal Pericyte in STZ-diabetic Mouse Model
CTL OIR-CTL
OIR-PVPC
isolectin
Isolectin DiO
isolectin
Isolectin DiO
isolectin
Transplanted hESC-PVPCs injected at Mouse OIR Model
Transplanted hESC-PVPCs injected at STZ-diabetic Retinopathy Model survived within Perivascular Region
Cardiomyocytes Program
hESC-Cardiomyocyte
Synchronization of Contraction under Bio-fule System
+ -
Ion channel changes in cardiomyocytes stimulated by enzyme conductivity
Ca2+
Myocardial infarction model
Before operation After operation
Int’l J Cardiology, 2013
Int’l J Cardiology, 2013
Thank to ..
Lee DR CHA Stem Cell Institute of CHA UniversityKim SJ Samsung Medical CenterKim SJ Seoul National Univ. School of MedicineKim JH Korea University Kang SW Korea University Ansan Hospital Kim HB Hanyang Univ. School of MedicineCho SW Yonsei UniversityKim HH Dankook University
Research Collaborators
Total 151 papers published in SCI-journal 68 papers published during recent 4 years (‘2010-’) in stem cell fieldPatent registration: 48 (domestic) cases, 6 (USA) cases Grants: \ 6,892,000,000 during recent 3 years (‘2010-’)
Representative Research Product